238 related articles for article (PubMed ID: 12623420)
21. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.
Bowen AL; Zomas A; Emmett E; Matutes E; Dyer MJ; Catovsky D
Br J Haematol; 1997 Mar; 96(3):617-9. PubMed ID: 9054672
[TBL] [Abstract][Full Text] [Related]
22. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
Hu Z; Li S; Medeiros LJ; Sun T
Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
[TBL] [Abstract][Full Text] [Related]
23. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
Jain P; Aoki E; Keating M; Wierda WG; O'Brien S; Gonzalez GN; Ferrajoli A; Jain N; Thompson PA; Jabbour E; Kanagal-Shamanna R; Pierce S; Alousi A; Hosing C; Khouri I; Estrov Z; Cortes J; Kantarjian H; Ravandi F; Kadia TM
Ann Oncol; 2017 Jul; 28(7):1554-1559. PubMed ID: 28379307
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.
Hu Z; Medeiros LJ; Fang L; Sun Y; Tang Z; Tang G; Sun T; Quesada AE; Hu S; Wang SA; Pei L; Lu X
Am J Hematol; 2017 May; 92(5):441-447. PubMed ID: 28194886
[TBL] [Abstract][Full Text] [Related]
25. T-cell prolymphocytic leukemia: A rare disease in an elderly female.
Madaris L
J Am Acad Nurse Pract; 2010 Dec; 22(12):648-53. PubMed ID: 21129072
[TBL] [Abstract][Full Text] [Related]
26. Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature.
Lee SS; Robinson MR; Morris JC; Mirtsching BC; Shen D; Chan CC
Surv Ophthalmol; 2004; 49(5):525-36. PubMed ID: 15325197
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804
[TBL] [Abstract][Full Text] [Related]
28. B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia.
Ruchlemer R; Parry-Jones N; Brito-Babapulle V; Attolico I; Wotherspoon AC; Matutes E; Catovsky D
Br J Haematol; 2004 May; 125(3):330-6. PubMed ID: 15086413
[TBL] [Abstract][Full Text] [Related]
29. Similarities between T-cell chronic lymphocytic leukemia and the small-cell variant of T-prolymphocytic leukemia.
Matutes E; Catovsky D
Blood; 1996 Apr; 87(8):3520-1. PubMed ID: 8605373
[No Abstract] [Full Text] [Related]
30. Advances and Perspectives in the Treatment of T-PLL.
Braun T; von Jan J; Wahnschaffe L; Herling M
Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
[TBL] [Abstract][Full Text] [Related]
31. Translocations t(X;14)(q28;q11) and t(Y;14)(q12;q11) in T-cell prolymphocytic leukemia.
de Oliveira FM; Tone LG; Simões BP; Rego EM; Marinato AF; Jácomo RH; Falcão RP
Int J Lab Hematol; 2009 Aug; 31(4):453-6. PubMed ID: 18294235
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
[TBL] [Abstract][Full Text] [Related]
33. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.
Cuneo A; Bigoni R; Rigolin GM; Roberti MG; Bardi A; Cavazzini F; Milani R; Minotto C; Tieghi A; Della Porta M; Agostini P; Tammiso E; Negrini M; Castoldi G
Haematologica; 2002 Jan; 87(1):44-51. PubMed ID: 11801464
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
Hasanali ZS; Saroya BS; Stuart A; Shimko S; Evans J; Vinod Shah M; Sharma K; Leshchenko VV; Parekh S; Loughran TP; Epner EM
Sci Transl Med; 2015 Jun; 7(293):293ra102. PubMed ID: 26109102
[TBL] [Abstract][Full Text] [Related]
35. Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization.
Maljaei SH; Brito-Babapulle V; Hiorns LR; Catovsky D
Cancer Genet Cytogenet; 1998 Jun; 103(2):110-6. PubMed ID: 9614908
[TBL] [Abstract][Full Text] [Related]
36. B- and T-cell prolymphocytic leukemia: antibody approaches.
Dearden C
Hematology Am Soc Hematol Educ Program; 2012; 2012():645-51. PubMed ID: 23233647
[TBL] [Abstract][Full Text] [Related]
37. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
Dumont FJ
Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
[TBL] [Abstract][Full Text] [Related]
38. A pediatric case of T-cell prolymphocytic leukemia.
Mitton B; Coutre S; Willert J; Schlis K; Porteus M; Kharbanda S; Agarwal-Hashmi R
Pediatr Blood Cancer; 2015 Jun; 62(6):1061-2. PubMed ID: 25417638
[TBL] [Abstract][Full Text] [Related]
39. Translocation (8;14)(q24;q32) as the sole cytogenetic abnormality in B-cell prolymphocytic leukemia.
Kuriakose P; Perveen N; Maeda K; Wiktor A; Van Dyke DL
Cancer Genet Cytogenet; 2004 Apr; 150(2):156-8. PubMed ID: 15066324
[TBL] [Abstract][Full Text] [Related]
40. B and T cell prolymphocytic leukaemia.
Cross M; Dearden C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
